

Resource Summary Report

Generated by [NIF](#) on Aug 1, 2026

CD152 (CTLA-4)

RRID:AB_2737762

Type: Antibody

Proper Citation

BD Biosciences Cat# 562743, RRID:AB_2737762

Antibody Information

URL: http://antibodyregistry.org/AB_2737762

Proper Citation: BD Biosciences Cat# 562743, RRID:AB_2737762

Target Antigen: CD152 (CTLA-4)

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: CD152 (CTLA-4)

Description: This monoclonal targets CD152 (CTLA-4)

Target Organism: baboon, cynomolgus, rhesus, human

Clone ID: BNI3

Antibody ID: AB_2737762

Vendor: BD Biosciences

Catalog Number: 562743

Record Creation Time: 20250819T214849+0000

Record Last Update: 20250820T001044+0000

Ratings and Alerts

No rating or validation information has been found for CD152 (CTLA-4).

No alerts have been found for CD152 (CTLA-4).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Awad MM, et al. (2022) Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. *Cancer cell*, 40(9), 1010.

Seki D, et al. (2021) Aberrant gut-microbiota-immune-brain axis development in premature neonates with brain damage. *Cell host & microbe*, 29(10), 1558.

Ott PA, et al. (2020) A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. *Cell*, 183(2), 347.